Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dopamine Synthesis Changes with Bupropion vs Escitalopram in MDD
NCT06675851Phase 4Recruiting
- Sponsor
- Medical University of Vienna
- Start
- Dec 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of bupropion in major depressive disorder (MDD) (3 arms), sponsored by Medical University of Vienna. Primary endpoints: Changes of the reward specific dopamine synthesis rate in the nucleus accumbens, Relationship between potential changes of the reward-specific dopamine synthesis rate and treatment response and 1 more. Started Dec 2022; status: recruiting.
02
Drugs
bupropion
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06675851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06675851.